Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia with Daridorexant in Canada

Conditions de participation

• Sexe:

  ALL

• Âges admissibles:

  18 and up

Critères de participation

Inclusion Criteria:

* Signed ICF prior to any study-mandated procedure.
* Has received a first prescription of daridorexant 50 mg to treat insomnia, treatment start has not exceeded 7 days prior to enrollment.
* Ability to read and understand French or English.

Exclusion Criteria:

* Patients participating in a clinical trial.
* History of daridorexant use in the past (i.e., samples provided by the physician before prescription).
* Taking a concomitant medication to treat insomnia.
* Already started daridorexant more than 7 days prior to enrollment.The 7-day period is necessary to allow flexibility between the time of prescription and PROxy first contact to participant. Beyond this 7-day period, patients may already have experienced benefits from daridorexant. To minimize bias in baseline results, these patients will be excluded.